Spar Nord Bank A/S
1.2.2021 10:59:18 CET | Globenewswire | Press release
Spar Nord Bank A/S' ("Spar Nord") acquisition of P/F BankNordik's ("BankNordik") Danish business has now been completed. With reference to Spar Nord's company announcement no. 26 of 22 December 2020 regarding Spar Nord's acquisition of BankNordik's Danish business, Spar Nord hereby announces that the transaction, following compliance with all formal conditions and resolution of sundry practical issues, has now been finally completed. The business acquired by Spar Nord will consequently be recognised in the bank’s balance sheet and income statement as of today. Please direct any questions regarding this release to Lasse Nyby, Chief Executive Officer, on tel. +45 9634 4011, or Rune Børglum Sørensen, Head of Investor Relations, on tel. + 45 9634 4236. Rune Børglum Sørensen Head of Investor Relations
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Chery Auto20.9.2026 06:23:11 CEST | Press release
LEPAS Expands Global Presence with Progress Across Multiple Markets
Sunwin20.9.2026 05:13:15 CEST | Press release
MG Commercial Makes IAA Transportation 2026 Debut with Two All-Electric Buses
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
